论文部分内容阅读
目的:探讨DNA甲基转移酶(DNMT)1与EZH2在急性髓系白血病(AML)中的表达及其相关性、临床意义。方法:采用荧光定量PCR技术检测50例AML患者骨髓细胞中DNMT1与EZH2mRNA的表达水平,分析DNMT1表达水平与临床特征和预后的关系以及与EZH2的相关性。结果:50例AML患者骨髓细胞中DNMT1mRNA的表达显著高于30例正常供者(2.72±0.73 vs 0.89±0.27,P<0.01);EZH2的表达水平也显著高于正常供者(4.39±1.06 vs 1.87±0.33,P<0.01);EZH2与DNMT1的表达水平呈显著正相关(r=0.51,P=0.002);DNMT1表达水平与外周血幼稚细胞比例≥60%(P<0.05)、白细胞计数≥50×109/L(P<0.05)显著相关;DNMT1高表达组患者中位生存时间15个月(95%CI:9-19个月),显著低于DNMT1低表达组患者的32个月(95%CI:27-40个月)(P=0.006)。结论:DNMT1和EZH2在AML患者中均高表达,两者表达水平呈正相关,DNMT1与AML患者预后不良相关。
Objective: To investigate the expression of DNA methyltransferase (DNMT) 1 and EZH2 in acute myeloid leukemia (AML) and their correlation and clinical significance. Methods: The expression of DNMT1 and EZH2 mRNA in 50 AML patients was detected by real-time PCR. The relationship between DNMT1 expression and clinical features and prognosis and EZH2 was analyzed. Results: The expression of DNMT1 mRNA in 50 AML patients was significantly higher than that in 30 normal donors (2.72 ± 0.73 vs 0.89 ± 0.27, P <0.01). The expression of EZH2 was also significantly higher than that in normal donors (4.39 ± 1.06 vs 1.87 ± 0.33, P <0.01). There was a significant positive correlation between EZH2 expression and DNMT1 expression (r = 0.51, P = 0.002). The ratio of DNMT1 expression to peripheral blood mononuclear cells was higher than 60% 50 × 109 / L (P <0.05). The median survival time of patients with DNMT1 overexpression group was 15 months (95% CI: 9-19 months), which was significantly lower than that of patients with DNMT1 low expression group for 32 months 95% CI: 27-40 months) (P = 0.006). Conclusion: Both DNMT1 and EZH2 are highly expressed in AML patients. The expression of DNMT1 and EZH2 are positively correlated with each other. DNMT1 is associated with poor prognosis in AML patients.